---
title: A Phase I Study of the DNA-PK Inhibitor Peposertib in Combination with Radiotherapy
  with or without Cisplatin in Patients with Advanced Head and Neck Tumors
date: '2023-09-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37751793/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230927180809&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: Peposertib in combination with palliative RT was well-tolerated
  up to doses of 200 mg QD as tablet with each RT fraction. When combined with RT
  and cisplatin, a tolerable peposertib dose yielded insufficient ...'
disable_comments: true
---
CONCLUSION: Peposertib in combination with palliative RT was well-tolerated up to doses of 200 mg QD as tablet with each RT fraction. When combined with RT and cisplatin, a tolerable peposertib dose yielded insufficient ...